Brian Feingold

Brian Feingold

Auto-generated profile, based on publicly available information

Brian Feingold

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
BFBrian Feingold
Brian Feingold
PBPam Bowman
Pam Bowman
AZAdriana Zeevi
Adriana Zeevi
AGAlin L. Girnita
Alin L. Girnita
EQEric S. Quivers
Eric S. Quivers
SWSteven A. Webber
Steven A. Webber

17 October 2011 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
BFBrian Feingold
Brian Feingold
JZJie Zheng
Jie Zheng
YLYuk M. Law
Yuk M. Law
WMW. Robert Morrow
W. Robert Morrow
THTimothy M. Hoffman
Timothy M. Hoffman
TIthe Pediatric Heart Transplant Study Investigators
the Pediatric Heart Transplant Study Investigators

22 September 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DMDefne A. Magnetta
Defne A. Magnetta
JGJustin Godown
Justin Godown
SWShawn C. C West
Shawn C. C West
MZMatthew Zinn
Matthew Zinn
KRKirsten Rose-Felker
Kirsten Rose-Felker
BFBrian Feingold
Brian Feingold
US pediatric heart allocation policy was recently revised, deprioritizing candidates with cardiomyopathy while maintaining status 1A eligibility for congenital heart disease (CHD) candidates on “high‐dose” inotropes. We compared waitlist characteristics and mortality around this change. Status 1A listings decreased (70% to 56%, P < .001) and CHD representation increased among status 1A listings (48% vs 64%, P < .001). Waitlist mortality overall (subdistribution hazard ratio [SHR] 0.96, P = .63) and among status 1A candidates (SHR 1.16, P = .14) were unchanged. CHD waitlist mortality trended better (SHR 0.82, P = .06) but was unchanged for CHD candidates listed status 1A (SHR 0.92, P = .47). Status 1A listing exceptions increased 2‐ to 3‐fold among hypertrophic and restrictive cardiomyopathy candidates and 13.5‐fold among dilated cardiomyopathy (DCM) candidates. Hypertrophic (SHR 6.25, P = .004) and restrictive (SHR 3.87, P = .03) cardiomyopathy candidates without status 1A exception had increased waitlist mortality, but those with DCM did not (SHR 1.26, P = .32). Ventricular assist device (VAD) use increased only among DCM candidates ≥1 years old (26% vs 38%, P < .001). Current allocation policy has increased CHD status 1A representation but has not improved their waitlist mortality. Excessive DCM status 1A listing exceptions and continued status 1A prioritization of children on stable VADs potentially diminish the intended benefits of policy revision.

1 December 2017 in American Heart Journal
Verified
Journal Article
Closed access
JGJustin Godown
Justin Godown
CTCary Thurm
Cary Thurm
DDDebra A. Dodd
Debra A. Dodd
JSJonathan H. Soslow
Jonathan H. Soslow
BFBrian Feingold
Brian Feingold
MHMatt Hall
Matt Hall

29 March 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MMMassimo Mangiola
Massimo Mangiola
MEMitchell A. Ellison
Mitchell A. Ellison
MMMarilyn Marrari
Marilyn Marrari
CBCarol Bentlejewski
Carol Bentlejewski
JSJohn Sadowski
John Sadowski
AZAdriana Zeevi
Adriana Zeevi

1 January 2013 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
BFBrian Feingold
Brian Feingold
SPSeo Young Park
Seo Young Park
DCDiane M. Comer
Diane M. Comer
CPCharity Patterson
Charity Patterson
SWSteven A. Webber
Steven A. Webber
CBCindy L. Bryce
Cindy L. Bryce